CBER is unanimously against Elevdiys’ return to the market without additional evidence, according to media reports citing an ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

March 17 (Reuters) - Shares of Sarepta Therapeutics Inc (SRPT.O), opens new tab slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Hoang from Citi maintained a Hold rating on the stock ...

William Blair notes that Sarepta Therapeutics Inc.’s SRPT Elevidys, supported by its expanded label, is expected to generate approximately $700 million annually in revenue for fiscal years 2025 ...